Tripsitter Psychedelics blog.seniorennet.be - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from blog.seniorennet.be Daily Mail and Mail on Sunday newspapers.
Barcelona, Spain - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines, has started marketing XEMBIFY®, its 20% subcutaneous immunoglobulin, in Spain. This plasma medicine is indicated for treating primary immunodeficiencie.
June 26, 2023 Grifols begins European launch of XEMBIFY® in Spain to treat immunodeficiencies Print this news Download the press release Primary immunodeficiencies (PID) affect.